Late Diagnosis of Hepatitis B and C Remains a Global Challenge

Why It Matters

Late identification drives severe liver disease, higher healthcare costs, and preventable deaths, making early screening a public‑health imperative for both insurers and providers.

Key Takeaways

• Late diagnosis rates: 11‑70% HCV, 15‑51% HBV
• Men over 40 most likely diagnosed late
• Diabetes and alcohol misuse double late‑diagnosis risk
• Fewer physician visits correlate with delayed detection
• Targeted screening in high‑risk groups improves early diagnosis

Pulse Analysis

Chronic hepatitis B and C continue to exact a heavy toll worldwide because the infections often remain asymptomatic for decades. Patients who are unaware of their status typically present only after liver fibrosis, cirrhosis, or hepatocellular carcinoma have developed, leading to markedly higher hospitalization rates and a four‑fold increase in mortality. The economic burden extends beyond direct medical costs, affecting productivity and long‑term care expenditures, which underscores why early detection is a critical lever for health‑system sustainability.

The review pinpoints several demographic and clinical red flags that signal a higher likelihood of delayed diagnosis. Men over 40, especially those with diabetes or a history of alcohol misuse, are consistently diagnosed later than their counterparts. Reduced interaction with the health system—fewer primary‑care visits or limited screening opportunities—exacerbates the problem, while women, people who inject drugs, and HIV‑co‑infected individuals benefit from targeted testing programs. Immigrant populations face a mixed picture: language barriers and stigma can delay care, yet focused outreach in some regions accelerates detection.

Policy makers and health‑care leaders can translate these insights into actionable strategies. Embedding hepatitis B and C tests into routine panels for high‑risk groups—such as older men with metabolic disorders—mirrors successful HIV screening models and can capture infections before irreversible damage occurs. Incentivizing regular primary‑care engagement, expanding point‑of‑care testing, and leveraging electronic health‑record alerts for at‑risk patients are practical steps. As data gaps narrow and real‑world evidence grows, a coordinated, risk‑based approach promises to shrink the late‑diagnosis gap and improve outcomes for millions worldwide.